APAnna Pliássova

Anna Pliássova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Pliássova has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adenosine A2A receptors control generalization of contextual fear in rats

    by Ana P. Simões, Marina A. M. Portes, Cátia R. Lopes, Felipe Vanz, Vanessa S. Lourenço, Anna Pliássova, Ingride L. Gaspar, Henrique B. Silva, Ângelo R. Tomé, Paula M. Canas, et al.

    Fear learning is essential to survival, but traumatic events may lead to abnormal fear consolidation and overgeneralization, triggering fear responses in safe environments, as occurs in post-traumatic stress disorder (PTSD). Adenosine A2A receptors (A2AR) control emotional memory and fear conditioning, but it is not known if they affect the consolidation and generalization of fear, which was now investigated. We now report that A2AR blockade through systemic administration of the A2AR antagonist SCH58261 immediately after contextual fear conditioning (within the consolidation window), accelerated fear generalization. Conversely, A2AR activation with CGS21680 decreased fear generalization. Ex vivo electrophysiological recordings of field excitatory post-synaptic potentials (fEPSPs) in CA3-CA1 synapses and of population spikes in the lateral amygdala (LA), showed that the effect of SCH58261 is associated with a reversion of fear conditioning-induced decrease of long-term potentiation (LTP) in the dorsal hippocampus (DH) and with increased amplitude of LA LTP in conditioned animals. These data suggest that A2AR are engaged during contextual fear consolidation, controlling long-term potentiation mechanisms in both DH and LA during fear consolidation, impacting on fear generalization; this supports targeting A2AR during fear consolidation to control aberrant fear processing in PTSD and other fear-related disorders.


  • An optimized spectrophotometric assay reveals increased activity of enzymes involved in 2‐arachidonoyl glycerol turnover in the cerebral cortex of a rat model of Alzheimer’s disease

    by Matilde S. Rodrigues, Cláudia Ferreira, Cândida Dias, Anna Pliássova, Lisiane Souza, Ana Ledo, João Laranjinha, Rodrigo A. Cunha, Attila Köfalvi

    The endocannabinoid system is implicated in a plethora of neuropsychiatric disorders. However, it is technically challenging to assess the turnover of 2‐arachidonoyl glycerol (2‐AG), the principal endocannabinoid molecule in the brain. Two recent studies showed that diacylglycerol lipase α (DAGLα), an enzyme chiefly responsible for the cerebral production of 2‐AG, also accepts the surrogate chromogenic substrate 4‐nitrophenyl butyrate (4‐NPB). Here we aimed to optimize this spectrophotometric assay for ex vivo brain tissue, in particular, rat cerebrocortical homogenates, to measure the activity of the major enzymes responsible for the production and degradation of 2‐AG. The initial velocity of 4‐NPB hydrolysis was dependent on protein, substrate and Ca2+ concentrations, and was sensitive to the non‐selective serine hydrolase inhibitor, methoxy arachidonyl fluorophosphonate, the DAGLα inhibitors, OMDM188, tetrahydrolipstatin and RHC80267, as well as the monoacylglycerol lipase (MAGL) inhibitor, JZL184, respectively. Next, we tested the usefulness of this assay in ex vivo brain tissue of rat models of human health conditions known to affect cerebrocortical 2‐AG production, i.e. pathological stress and sporadic Alzheimer’s disease (AD). In rats submitted to chronic restraint stress, cortical CB1R density was significantly decreased, as assessed with radioligand binding. Nevertheless, 4‐NPB hydrolysis remained at control levels. However, in rats 4 weeks after intracerebroventricular injection with streptozotocin – an established model of sporadic AD –, both CB1R levels and 4‐NPB hydrolysis and its DAGL‐ and MAGL‐dependent fractions were significantly increased. Altogether, we optimized a simple complementary ex vivo technique for the quantification of DAGL and MAGL activity in brain samples.


  • Control of NMDA Receptor-Mediated Currents by Adenosine A 1 and A 2A Receptors Within the Basolateral Amygdala

    by Anna Pliássova, Margarida Henriques, Henrique B. Silva, Paula Agostinho, Rodrigo A. Cunha, Samira G. Ferreira

    Background: The amygdala is a key brain region involved in emotional processing. Activity of its cells is modulated by adenosine, via both A 1 and A 2A receptors (A 1 R and A 2A R). A 1 R and A 2A R control fear memory, a process critically dependent on NMDA receptors (NMDAR). Thus, we now tested whether A 1 R and A 2A R control NMDAR in the amygdala. Materials and Methods: We recorded synaptically evoked NMDAR-mediated excitatory post-synaptic currents (NMDA-EPSCs) in pyramidal cells of the basolateral amygdala, upon stimulation of the lateral amygdala in brain slices from 4- to 6-week-old male Wistar rats. Results: Activation of A 1 R decreased NMDAR-mediated currents. Surprisingly, activation of A 2A R with CGS21680 (30 nM) also decreased NMDAR-mediated synaptic currents, an effect prevented by the A 1 R antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) rather than by the selective A 2A R antagonist SCH58261. Conclusions: Our data suggest that adenosine primarily inhibits intra-amygdalar circuits through A 1 R activation.


  • Blockade of adenosine A2A receptors recovers early deficits of memory and plasticity in the triple transgenic mouse model of Alzheimer's disease

    by António C. Silva, Cristina Lemos, Francisco Q. Gonçalves, Anna V. Pliássova, Nuno J. Machado, Henrique B. Silva, Paula M. Canas, Rodrigo A. Cunha, João Pedro Lopes, Paula Agostinho


  • Age-Related Changes in the Synaptic Density of Amyloid-β Protein Precursor and Secretases in the Human Cerebral Cortex

    by Anna Pliássova, Paula M. Canas, Ana Carolina Xavier, Beatriz S. da Silva, Rodrigo A. Cunha, Paula Agostinho

    Amyloid-β protein precursor (AβPP) is involved in synaptic formation and function. In the human cingulate cortex, AβPP was preferentially located in the presynaptic active zone as in rodents, indicating a preserved subsynaptic AβPP distribution across species and brain regions. Synaptic AβPP immunoreactivity was decreased with aging in cortical samples collected from autopsies of males (20-80 years), whereas the synaptic levels of α -secretase (ADAM10) and β-secretase (BACE1) did not significantly change. Decreased AβPP levels may be related to lower allostasis of synapses in the aged brain and their greater susceptibility to dysfunction characteristic of the onset of neurodegenerative disorders.


  • The Association of Amyloid-β Protein Precursor With α- and β-Secretases in Mouse Cerebral Cortex Synapses Is Altered in Early Alzheimer’s Disease

    by Anna Pliássova, João P. Lopes, Cristina Lemos, Catarina R. Oliveira, Rodrigo A. Cunha, Paula Agostinho

    Amyloid-β peptides (Aβ), the proposed triggers of synaptic dysfunction in early Alzheimer’s disease (AD), derive from the endoproteolytic cleavage of amyloid-β precursor protein (APP) by β-secretases (BACE1), whereas APP cleavage by α-secretases (ADAM10) abrogates Aβ formation. We now mapped the synaptic localization of APP, ADAM10, and BACE1 in the mouse cerebral cortex. All three proteins were present in cortical synapses and subsynaptic fractionation revealed that APP was located mainly in the pre-synaptic active zone (53 %) and in the post-synaptic density (37 %), whereas ADAM10 was enriched in the post-synaptic density (61 %) and BACE1 was concentrated in extra-synaptic regions (72 %). Immunocytochemistry analysis further showed that APP and BACE1 were co-localized in about 30 % of both glutamatergic and GABAergic terminals, whereas few terminals were endowed with ADAM10. This distribution is modified in a mouse model of early AD based on Aβ1–42-intracerebroventricular injection, where the synaptic levels of APP and ADAM10 increased by 30 %, whereas BACE1 levels were reduced. This suggests that, in early AD, there are compensatory mechanisms to avoid Aβ overload in cortical synapses favoring the non-amyloidogenic processing of APP.


  • Localization and Trafficking of Amyloid-β Protein Precursor and Secretases: Impact on Alzheimer's Disease

    by Paula Agostinho, Anna Pliássova, Catarina R. Oliveira, Rodrigo A. Cunha

    Alzheimer's disease (AD) affects almost 35 million people worldwide. One of the neuropathological features of AD is the presence of extracellular amyloid plaques, which are mainly composed of amyloid-β (Aβ) peptides. These peptides derive from the am


  • Adenosine A2breceptors control A1receptor‐mediated inhibition of synaptic transmission in the mouse hippocampus

    by Francisco Q. Gonçalves, Johny Pires, Anna Pliassova, Rui Beleza, Cristina Lemos, Joana M. Marques, Ricardo J. Rodrigues, Paula M. Canas, Attila Köfalvi, Rodrigo A. Cunha, et al.

    Adenosine is a neuromodulator mostly acting through A1(inhibitory) and A2A(excitatory) receptors in the brain. A2Breceptors (A2BR) are Gs/q‐protein‐coupled receptors with low expression in the brain. As A2BRfunction is largely unknown, we have now explored their role in the mouse hippocampus. We performed electrophysiological extracellular recordings in mouse hippocampal slices, and immunological analysis of nerve terminals and glutamate release in hippocampal slices and synaptosomes. Additionally, A2BR‐knockout (A2BR‐KO) and C57/BL6 mice were submitted to a behavioural test battery (open field, elevated plus‐maze, Y‐maze). The A2BRagonistBAY60‐6583 (300 nm) decreased the paired‐pulse stimulation ratio, an effect prevented by the A2BRantagonistMRS 1754 (200nM) and abrogated in A2BR‐KOmice. Accordingly, A2BRimmunoreactivity was present in 73 ± 5% of glutamatergic nerve terminals, i.e. those immunopositive for vesicular glutamate transporters. Furthermore,BAY 60‐6583 attenuated the A1R control of synaptic transmission, both the A1R inhibition caused by 2‐chloroadenosine (0.1–1 μm) and the disinhibition caused by the A1R antagonistDPCPX(100 nm), both effects prevented byMRS 1754 and abrogated in A2BR‐KOmice.BAY 60‐6583 decreased glutamate release in slices and also attenuated the A1R inhibition (CPA100 nm). A2BR‐KOmice displayed a modified exploratory behaviour with an increased time in the central areas of the open field, elevated plus‐maze and the Y‐maze and no alteration of locomotion, anxiety or working memory. We conclude that A2BRare present in hippocampal glutamatergic terminals where they counteract the predominant A1R‐mediated inhibition of synaptic transmission, impacting on exploratory behaviour.


  • Hyperactivation of D1 and A2A receptors contributes to cognitive dysfunction in Huntington's disease

    by Shiraz Tyebji, Ana Saavedra, Paula M. Canas, Anna Pliassova, José M. Delgado-García, Jordi Alberch, Rodrigo A. Cunha, Agnès Gruart, Esther Pérez-Navarro